Long-term administration of prolactin or testosterone induced similar precancerous prostate lesions in rats by Herrera-Covarrubias, D. et al.
Experimental Oncology 37, 13–18, 2015 (March) 13
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Evidence indicates that prolactin plays a crucial role in the normal function and development of the prostate, but abnormal high 
levels of the hormone are associated with hyperplasia and cancer of the gland. Aims: The present study was designed to describe 
the progressive specific histological abnormalities in the prostate of rats with chronic hyperprolactinemia. Material and Methods: 
Prolactin was administered during 4; 12 or 24 weeks, and the resulting prostatic alterations were compared with control rats, and 
also with those treated with testosterone, or the combination of prolactin + testosterone. Results: Rats treated with prolactin, 
testosterone or prolactin + testosterone expressed precancerous histological abnormalities in the dorsolateral and ventral portions 
of the prostate as early as in 4 weeks of treatment, but in all cases the malignancy increased after 12 or 24 weeks of treatment. 
Conclusion: Our study confirms that chronic hyperprolactinemia is a cause of prostate precancerous pathologies.
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Among all types of tumors in men, prostate can-
cer (CaP) is the second most common worldwide 
(≈ 15%) [1]. Every year, hundreds of thousands of new 
cases of CaP are detected and up to 6.6% of them re-
sult in death [1]. The etiology of the disease is diverse, 
and may include family history, age (> 65) [2], race 
(> african-ancestry) [3], diet (> high-fat products) [4], 
obesity (body mass index (BMI) > 25) [5], and bad 
habits, such as smoking [6]. For that reason, treatments 
are also diverse and may include surgery, radiation, che-
motherapy, vaccines, or hormone treatments. The latter 
is mainly focused on the androgen deprivation therapy 
(ADT), and it is perhaps, the first choice therapy [7].
The goal of ADT is to reduce the levels of androgens 
that reach the prostate. ADT can slow down the growth 
of the gland and may decrease its size. CaP has been 
classically associated with androgens not only because 
they induce cell division, but also because they are as-
sociated with spontaneous mutations that result in more 
and abnormal cells within the gland [8, 9]. Paradoxically, 
by the age of 65 the blood levels of androgens, i.e. tes-
tosterone (T) decrease by more than 50% as compared 
to the levels observed at age 20 [10–13], and other hor-
mones such as prolactin (PRL) increase by at least 30% 
above normal levels in elderly [14]. A similar shift in the 
concentrations of those hormones is observed in studies 
of the prostate of laboratory rats. For instance, treatment 
with dopamine blockers results in a twofold increase 
of serum PRL in males, but also results in a twofold de-
crease in T [15]. PRL has both direct and indirect effects 
on the gland, and interacts with androgens in normal 
and abnormal processes [16, 17]. In fact, CaP patients 
express higher blood levels of PRL and less T [18], 
as compared to healthy people of the same age [19–21].
Animal models and cell lines support the idea 
that PRL, via its receptor (PRLR), activates the Jak2-
Stat5a/b pathway that may result in tumorige-
nesis [22]. So far, studies on laboratory rats have 
shown that treatment with PRL results in enlargement 
of the prostate [17, 23], suggesting that high levels 
participate in the histological alterations in the gland. 
However, the timed progression and the specific 
histological alterations caused by high levels of PRL 
during long periods have not been described yet. Thus, 
in the present study we assessed the effects of treat-
ment with PRL during 4; 12 or 24 weeks on labora-
tory rats in comparison with treatment with T alone, 
or PRL + T combination. We hypothesized that PRL 
would induce prostatic precancerous lesions as severe 
as those induced by T. In addition, we hypothesized 
that PRL + T combination would induce more severe al-
terations than either of the two hormones given alone.
MATERIAL AND METHODS
Animals. Fifty-four Wistar male rats were used 
(Rattus norvegicus albinus). They were purchased 
from a certified animal supplier in Mexico (Rismart®) 
and were 12 weeks old at the start of the study. The 
rats were housed in large plexiglas cages (50 × 30 × 
20 cm), and kept in a colony room at the Center for 
Brain Research, University of Veracruz in a 12–12 h re-
verse Light-Dark cycle (lights off at 8:00 h). Water and 
commercial feed (Rismart® rat chow) were provided 
ad libitum. All the experimental procedures were ap-
proved by an admission committee of the graduate 
program in neuroetho logy, following the Official 
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Mexican Norm NOM-062-ZOO-1999 for use and care 
of laboratory animals.
Hormone treatments. Rats were randomly 
organized in 5 groups, depending on the hormone 
treatment they received. 1) The PRL group received 
intraperitoneal (i.p.) injections of ovine PRL (SIGMA®), 
of a dose of 1.7 IU diluted in 100 ml of injectable grade 
water, equivalent to 50 μg/100 ml of PRL every 12 h. 
2) The T group received a subcutaneous (s.c.) silastic 
implant in the back (Dow Corning Corp®. 062X0125 ID); 
filled with T propionate (100 mg/kg of body weight). 
The implant allowed the T propionate (T) to be con-
stantly released, which maintained high plasma levels 
of the hormone as previously shown [24]. 3) The PRL 
+ T group received both treatments. 4). The control 
group was injected with saline solution (0.9%) 100 μl, 
i.p. every 12 h, and received an empty s.c. implant 
in the back. 5) The intact group comprised the animals 
that received no treatment, but were handled during 
the same time as experimental animals. Each group was 
further divided in 3 subgroups, depending on the num-
ber of weeks they received treatment (4; 12, or 24).
Prostate samples and histology. One day after 
the end of hormone treatment of each group, the rats 
were deeply anesthetized with sodium pentobarbital 
(35 mg/kg i.p.). Then, the accessory sexual organs 
were carefully removed and placed into a container with 
isotonic saline solution. Anesthetized rats were then 
sacrificed with a second overdose of pentobarbital. 
The prostate was identified under a dissecting micro-
scope (MEJI, EMZ-TR®), and was further divided into 
ventral (VP) and dorsolateral (DLP) portions. The VP and 
DLP were immersed in formol 10% during 24 h, then 
dehydrated in alcohol 70% and 80% (1 h each), 95% 
(3×2 h each), and ethanol 100% overnight, and two 
more changes (1 h each) the following day, and finally 
in xylene (3×1 h each). The tissue was then embedded 
in paraffin wax 2×2 h each), sliced (5 µm thick) with 
a microtome (RM 2125RT Leica®), mounted on slides 
in a bath at 52 °C (containing pork skin-based gelatin 
2.5 mg/100 ml) and then processed for Hematoxylin-
Eosin dye technique as follows: 1 h at 57 °C, deparaf-
finization in xylene (3×5 min each), rehydrated in alco-
hol/xylene (1:1) 5 min, ethanol 96% 3 min, hematoxylin 
(10 min), water (30 s), acid alcohol (quick immersion), 
water (10 s), lithium carbonate (30 s), water (10 s), 
and eosin (4 quick immersions). Dehydration occurred 
in ethanol 96% (3 min), ethanol 100% (2 min), ethanol/
xylene 1:1 (2 min), and xylene (5 min). Then, permount 
was added and slides were coverslipped, air dried, and 
observed under a light microscope (Olympus Ax70). 
Photomicrographs were taken at × 40 magnification 
and analyzed by the same experimenter (DH).
RESULTS
A thorough analysis did not demonstrate any histo-
logical abnormalities in rats from groups 4 and 5 (con-
trol and intact, respectively) after 4; 12 or 24 weeks. 
In the DLP of intact rats the epithelium was cubic, ho-
mogeneous in size, with scarce papillae. The interstitial 
space was homogeneous and contained collagen-
like eosinophilic reticular areas. The cell nuclei were 
homogeneous in size, had a polar position towards 
the base with a nucleus-cytoplasm ratio (N:C) of 1:4, 
and chromatins were homogeneous and dispersed. 
The myoepithelium was euplasic and the pattern 
observed at low magnification was tubular (Fig. 1, a, 
e, i and Table 1). The VP of intact rats was also normal 
at 4; 12 or 24 weeks of observation. The epithelium was 
columnar, homogeneous in size, and formed scarce 
papillae. The interstitial space was homogeneous and 
contained collagen-like eosinophilic reticular areas. 
Nuclei were homogeneous in size, with a polar posi-
tion location towards the base, with a N:C ratio of 1:4, 
and the chromatins were homogeneous. The myoepi-
thelium was euplasic and the pattern observed at low 
magnification was tubular (Fig. 2, a, e, i and Table 2).
Unlike the rats from the intact or control groups, those 
treated with PRL, T or PRL + T displayed histological 
abnormalities in the DLP and VP as early as in 4 weeks 
of treatment, but the degree of malignancy in the le-
sions increased after 12 or 24 weeks. For instance, after 
4 weeks of treatment with PRL alone, the epithelium 
of the DLP was not longer cubic, but columnar (meta-
plasic). There was hyperthrophy and hyperplasia, the 
interstitial space was not longer observable, but was 
rather compressed, and the cell nuclei were heteroge-
neous in size (anisokaryiosis) [25, 26]. Other features 
such as myoepithelium, pattern, lumen content and 
chromatin were apparently normal at 4 weeks of treat-
ment, but were abnormal after 12 or 24 weeks. Specifi-
cally, after 12 or 24 weeks of treatment with PRL alone 
the epithelium showed dysplasia, there were many 
papillae, the interstice contained many mononuclear 
cells, there was anisokaryosis, the nuclei were not longer 
polar, the N:C ratio was abnormal 1:1, the chromatin was 
compact, and the myoepithelim was proplastic (Fig. 1, 
b, f, j and see Table 1). In the VP similar abnormalities were 
observed after 12 weeks of PRL (Fig. 2, b, f, j and see Table 2). 
The effects of treatment with T were identified ahead of those 
induced by PRL treatment. For example, with only four weeks 
of treatment rats that received T or PRL + T expressed more 
severe histological alterations than both the DLP and VP rats 
treated with PRL alone. The epithelium showed dysplasia 
(with T) or severe dysplasia (with PRL + T) within the first 
month. In addition, the N:C ratio was 1:1 in T or PRL + 
T groups, and the polarity of the nucleus was completely 
lost. Altogether, these data indicate that PRL alone was 
sufficient to induce precancerous alterations in the pros-
tate of rats. The lesions were similar to those caused 
by T alone at 12 or 24 weeks, but the latter induced more 
alterations during the first 4 weeks. In addition, the com-
bination of PRL + T increased the degree of malignancy, 
even after 4 weeks of treatment (Fig. 1, c, d, g, h, k, l and 
2, c, d, g, h, k, l).
DISCUSSION
Normal levels of PRL contribute to the growth and 
functioning of the prostate [27]. PRL and its recep-
tor (PRLR) are present in the gland during both fetal 
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development and adulthood [22, 28–30], and they 
are needed to maintain a normal weight and func-
tions of the prostate. In one study with pup rats the 
low levels of PRL (reduced with injections of a rabbit 
anti-rat PRL serum) resulted in significant reduction 
of the weights of the prostate and seminal vesicles 
[31]. By contrast, abnormal high PRL levels result 
in an enlargement of the prostate [17, 23, 24, 32]. 
Earlier we have reported that prostate enlarges in rats 
when PRL in blood during two continuous weeks 
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Fig. 1. Dorsolateral prostate (× 40). Rats were treated during 4; 12 or 24 weeks with prolactin (PRL), testosterone (T), both (PRL + T), 
or served as controls. Histological abnormalities were observed as early as 4 weeks of treatment (see Table 1 for details). Bar indicates 50 μm
Table 1. Dorsolateral prostate 
Dorsal-later-
al prostate
4 weeks 12 weeks 24 weeks
Intact PRL T PRL + T Intact PRL T PRL + T Intact PRL T PRL + T
Epithelium
Form cubic columnar dysplasia Severe 
dysplasia
cubic dysplasia dysplasia severe 
dysplasia
cubic dysplasia dysplasia severe 
dysplasia
Size even HT, HP anisocy-
tosis
anisocy-
tosis
even HT, HP anisocy-
tosis
anisocy-
tosis
even HT, HP anisocy-
tosis
anisocy-
tosis
Papillae scarce few few few few few few many few many many many 
Interstice
Space even com-
pressed
com-
pressed
com-
pressed
even com-
pressed
com-
pressed
com-
pressed
even com-
pressed
com-
pressed
com-
pressed
Content collagen-
like
collagen-
like
collagen-
like
collagen-
like
collagen-
like
mononu-
clear cells
mononu-
clear cells
mononu-
clear cells
collagen-
like
mononu-
clear cells
mononu-
clear cells
mononu-
clear
cells
Nucleus
Size even aniso-
karyosis
aniso-
karyosis
aniso-
karyosis
even anisokary-
osis
anisokary-
osis
anisokary-
osis
even anisokary-
osis
anisokary-
osis
anisokary-
osis
Location polar polar no polar no polar polar no polar no polar no polar polar no polar no polar no polar
N:C ratio 1:4 1:4 1:1 1:1 1:4 1:1 1:1 1:1 1:1 1:1 1:1 1:1
Myoepithelim euplasia euplasia proplasia proplasia euplasia proplasia proplasia proplasia euplasia proplasia proplasia proplasia
Pattern (4X) tubular tubular tubular cribriform tubular tubular/ 
cribriform
tubular amorphous tubular tubular/ 
cribriform
amorphous amorphous
Lumen
Content amor-
phous
amor-
phous
amor-
phous
amor-
phous
amor-
phous
amorphous nothing nothing amor-
phous
nothing nothing nothing
Chromatin dispersed dispersed compact compact dispersed compact compact compact dispersed compact compact compact
Rats were treated during 4; 12 or 24 weeks with prolactin (PRL), testosterone (T), both (PRL + T), or served as controls. Histological abnormalities were ob-
served as early as to 4 weeks of treatment. HT = hypertrophy, HP = hyperplasia. Nucleus-Cytoplasm ratio (N:C).
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reaches chronic steady levels of about 40 ng/ml [33] 
exceeding only by 5% the normal highest PRL levels 
expressed in every circadian cycle (12–38 ng/ml) [24]. 
Human patients with benign prostatic hyperplasia 
(BPH) have higher blood levels of PRL, and the same 
occurs in patients with CaP [21]. Prostate may not 
depend on pituitary PRL for its growth since the gland 
itself can produce PRL by its secretory epithelium 
[29]. Furthermore, high levels of PRL are also found 
in obese individuals, suggesting that the adipose tis-
sue itself may function as an endocrine organ [34–36]. 
Interestingly, the expression of PRLR is reduced 
Table 2. Ventral prostate 
Ventral pros-
tate
4 weeks 12 weeks 24 weeks
Intact PRL T PRL + T Intact PRL T PRL + T Intact PRL T PRL + T
Epithelium
Form columnar columnar dysplasia dysplasia columnar dysplasia dysplasia dysplasia columnar dysplasia dysplasia severe 
dysplasia
Size even HT, HP anisocy-
tosis
anisocy-
tosis
even HT, HP anisocy-
tosis
anisocy-
tosis
even HT, HP anisocy-
tosis
anisocy-
tosis
Papillae scarce few few few few few few many few many many many 
Interstice
Space even com-
pressed
com-
pressed
com-
pressed
even com-
pressed
com-
pressed
com-
pressed
even com-
pressed
com-
pressed
com-
pressed
Content collagen-
like
collagen-
like
collagen-
like
collagen-
like
collagen-
like
mononu-
clear cells
mononu-
clear cells
mononu-
clear cells
collagen-
like
mononu-
clear cells
mononu-
clear cells
mononu-
clear cells
Nucleus
Size even aniso-
karyosis
aniso-
karyosis
aniso-
karyosis
even anisokary-
osis
anisokary-
osis
anisokary-
osis
even anisokary-
osis
anisokary-
osis
anisokary-
osis
Location polar polar no polar no polar polar polar no polar no polar polar no polar no polar no polar
N:C ratio 1:4 1:4 1:1 1:1 1:4 1:1 1:1 1:1 1:1 1:1 1:1 1:1
Myoepithelim euplasia euplasia proplasia proplasia euplasia proplasia proplasia proplasia euplasia proplasia proplasia euplasia
Pattern (4X) tubular tubular tubular cribriform tubular tubular/
cribriform
tubular amorphous tubular tubular/
cribriform
amorphous amorphous
Lumen
Content amor-
phous
amor-
phous
amor-
phous
amor-
phous
amor-
phous
amorphous nothing nothing amor-
phous
nothing nothing nothing
Chromatin dispersed dispersed compact compact dispersed compact compact compact dispersed compact compact compact
Rats were treated during 4; 12 or 24 weeks with prolactin (PRL), testosterone (T), both (PRL+T), or served as controls. Histological abnormalities were ob-
served as early as to 4 weeks of treatment. HT = hypertrophy, HP = hyperplasia. Nucleus-Cytoplasm ratio (N:C).
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Fig. 2. Ventral prostate (×40). Rats were treated during 4; 12 or 24 weeks with prolactin (PRL), testosterone (T), both (PRL+T), or served 
as controls. Histological abnormalities were observed as early as 4 weeks of treatment (see Table 2 for details). Bar indicates 50 μm
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in prostate of the patients with the high grade cancer 
(>4 in Gleason scale) [28]. However, it has been ar-
gued that such reduction of PRLR may be associated 
with the presence of poorly differentiated prostatic 
cells, which express less PRLR [28].
Our results indicate that in rats, high levels of PRL 
during periods of 4 weeks or more result in histological 
alterations of the prostate that may be considered as pre-
cancerous. The PRL-induced lesions are very similar 
to those induced by T alone, but the combination of both 
hormones results in more severe histological alterations 
after 4 weeks. Anysokaryosis, polarity and alterations 
in N:C ratio indicate the changes in chromosome orga-
nization, which in turn can affect gene expression [37] 
resulting in dysplasia. In addition, the myoepithelium 
was proplastic, and the chromatin was compact, which 
indicate that both hormone treatments did activate cell 
division. In addition, the presence of mononuclear cells 
in the interstice and the absence of the luminal content 
(see Tables 1, 2), suggest the activation of inflammation 
mechanisms as well. The combination of PRL + T resulted 
in similar, but more severe alterations. These results also 
indicate a synergistic effect of two hormones in the de-
velopment of prostate pathology.
Therefore, according to the present study and 
 others [22, 38–40], individuals with chronic high levels 
of PRL for 4 weeks or more may express abnormal 
precancerous histological features in the prostate. 
Altogether, the data support the idea that regardless 
of the source of PRL (e.g. systemic, pituitary, prostatic, 
or adipose) it may be responsible of histological al-
terations of the prostate that may become precancer-
ous, even in individuals with low levels of androgens. 
In the last decade, some preclinical trials have also 
contri buted to understanding the positive effect of anti-
PRL treatment on CaP [41–44]. However, better out-
comes have been found with the combined suppression 
of androgens and PRL together [45]. Further research 
is needed to understand the specific role of these hor-
mones in the development and maintenance of prostate 
pathologies including cancer [46, 47].
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